Investigating the effectiveness of Nemolizumab, an IL-33 inhibitor, to treat prurigo nodularis
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on November 22nd, 2023
|
Prurigo nodularis, a persistent skin condition influenced by type 2 and type 17 helper T-cells (Th2 and Th17), has seen success with Dupilumab as an initial treatment, given its capacity to hinder IL-4 and IL-17 signaling. Since IL-33, a cytokine released by Th2 cells, is another prospective therapeutic target, a study aimed to evaluate the efficacy of Nemolizumab, an inhibitor of IL-33, in managing prurigo nodularis.
The phase 3 clinical trial included 274 patients who had been diagnosed with prurigo nodularis for at least 6 months. Using the Investigator’s Global Assessment score, researchers established that the cohort's baseline prurigo nodularis severity ranged from moderate to severe, typically indicated by a score of 7 or higher according to the Peak Pruritus Numerical Rating Scale (PP-NRS). Around 80% of the patients had previously undergone treatment with topical glucocorticoids, while 38% had utilized oral antihistamines. Random allocation assigned participants to receive either a placebo or Nemolizumab, administered subcutaneously every four weeks. Dosage varied based on weight, with 30 mg for individuals weighing less than 90 kg and 60 mg for those exceeding 90 kg. Following 16 weeks of treatment, Nemolizumab showcased notable effectiveness in reducing prurigo nodularis severity, assessed by the PP-NRS standard and the Investigator’s Global Assessment score. Encouragingly, clinical improvement became apparent within the initial two weeks of treatment. Assessment of side effects revealed that Nemolizumab was associated with a higher incidence of headache and atopic dermatitis.
The phase 3 clinical trial included 274 patients who had been diagnosed with prurigo nodularis for at least 6 months. Using the Investigator’s Global Assessment score, researchers established that the cohort's baseline prurigo nodularis severity ranged from moderate to severe, typically indicated by a score of 7 or higher according to the Peak Pruritus Numerical Rating Scale (PP-NRS). Around 80% of the patients had previously undergone treatment with topical glucocorticoids, while 38% had utilized oral antihistamines. Random allocation assigned participants to receive either a placebo or Nemolizumab, administered subcutaneously every four weeks. Dosage varied based on weight, with 30 mg for individuals weighing less than 90 kg and 60 mg for those exceeding 90 kg. Following 16 weeks of treatment, Nemolizumab showcased notable effectiveness in reducing prurigo nodularis severity, assessed by the PP-NRS standard and the Investigator’s Global Assessment score. Encouragingly, clinical improvement became apparent within the initial two weeks of treatment. Assessment of side effects revealed that Nemolizumab was associated with a higher incidence of headache and atopic dermatitis.